X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (589) 589
immunotherapy (550) 550
oncology (519) 519
humans (497) 497
anti-pd-1 (477) 477
nivolumab (357) 357
anti-pd-1 antibody (351) 351
melanoma (339) 339
cancer (338) 338
ipilimumab (286) 286
safety (282) 282
pembrolizumab (235) 235
immunology (224) 224
female (202) 202
pd-1 (182) 182
care and treatment (175) 175
metastatic melanoma (174) 174
male (171) 171
chemotherapy (166) 166
tumors (166) 166
metastasis (164) 164
blockade (156) 156
middle aged (153) 153
programmed cell death 1 receptor - antagonists & inhibitors (151) 151
apoptosis (147) 147
aged (145) 145
antibodies, monoclonal - therapeutic use (143) 143
open-label (135) 135
animals (132) 132
cancer therapies (132) 132
lymphocytes (128) 128
patients (126) 126
therapy (124) 124
antineoplastic agents - therapeutic use (122) 122
melanoma - drug therapy (121) 121
antibody (120) 120
survival (118) 118
pd-l1 (115) 115
research (111) 111
clinical trials (110) 110
immune checkpoint (110) 110
advanced melanoma (108) 108
expression (108) 108
programmed cell death 1 receptor - immunology (105) 105
adult (102) 102
lung cancer (102) 102
antibodies, monoclonal - adverse effects (99) 99
pd-1 blockade (96) 96
cell lung-cancer (95) 95
analysis (93) 93
antibodies (93) 93
treatment outcome (93) 93
t-cells (92) 92
t cells (91) 91
pd-1 protein (90) 90
immunotherapy - methods (88) 88
antineoplastic agents - adverse effects (86) 86
article (85) 85
review (84) 84
medicine, research & experimental (80) 80
cell death (79) 79
health aspects (79) 79
immune checkpoint inhibitors (76) 76
aged, 80 and over (75) 75
antigens (75) 75
anti-pd-1 therapy (74) 74
docetaxel (73) 73
ligands (73) 73
neoplasms. tumors. oncology. including cancer and carcinogens (73) 73
b7-h1 antigen - antagonists & inhibitors (72) 72
drug therapy (71) 71
antibodies, monoclonal, humanized - therapeutic use (70) 70
pharmacology & pharmacy (69) 69
mice (68) 68
immune system (66) 66
neoplasms - immunology (66) 66
skin neoplasms - drug therapy (66) 66
lymphocytes t (64) 64
prognosis (64) 64
anti-ctla-4 (63) 63
antibodies, monoclonal, humanized - adverse effects (63) 63
cytotoxicity (63) 63
medical prognosis (63) 63
melanoma - pathology (63) 63
adverse events (61) 61
cell biology (60) 60
immune response (60) 60
monoclonal antibodies (60) 60
neoplasms - drug therapy (60) 60
lung cancer, non-small cell (58) 58
pd-l1 protein (58) 58
usage (58) 58
lung neoplasms - drug therapy (57) 57
medical research (57) 57
responses (56) 56
immunoglobulins (55) 55
clinical activity (54) 54
tumor-infiltrating lymphocytes (54) 54
biomarkers (53) 53
toxicity (53) 53
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International Journal of Cancer, ISSN 0020-7136, 06/2018, Volume 142, Issue 11, pp. 2344 - 2354
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 54, pp. 139 - 148
Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3344 - 3353
Journal Article
by Arce Vargas, Frederick and Furness, Andrew J.S and Solomon, Isabelle and Joshi, Kroopa and Mekkaoui, Leila and Lesko, Marta H and Miranda Rota, Enrique and Dahan, Rony and Georgiou, Andrew and Sledzinska, Anna and Ben Aissa, Assma and Franz, Dafne and Werner Sunderland, Mariana and Wong, Yien Ning Sophia and Henry, Jake Y and O’Brien, Tim and Nicol, David and Challacombe, Ben and Beers, Stephen A and Spain, Lavinia and Wotherspoon, Andrew and Francis, Nicholas and Smith, Amy and Smith, Sean and Smith, Myles and Smith, Elaine and Strauss, Dirk and Hayes, Andrew and Soultati, Aspasia and Stares, Mark and Lynch, Joanna and Fotiadis, Nicos and Fernando, Archana and Hazell, Steve and Chandra, Ashish and Pickering, Lisa and Rudman, Sarah and Chowdhury, Simon and Swanton, Charles and Jamal-Hanjani, Mariam and Veeriah, Selvaraju and Shafi, Seema and Czyzewska-Khan, Justyna and Johnson, Benjamin and Johnson, Diana and Laycock, Joanne and Bosshard-Carter, Leticia and Goh, Gerald and Rosenthal, Rachel and Gorman, Pat and Murugaesu, Nirupa and Hynds, Robert E and Wilson, Gareth and Birkbak, Nicolai J and Watkins, Thomas B.K and McGranahan, Nicholas and Horswell, Stuart and Mitter, Richard and Escudero, Mickael and Stewart, Aengus and Van Loo, Peter and Rowan, Andrew and Xu, Hang and Turajlic, Samra and Hiley, Crispin and Abbosh, Christopher and Goldman, Jacki and Stone, Richard Kevin and Denner, Tamara and Matthews, Nik and Matthews, Sue and Elgar, Greg and Ward, Sophia and Biggs, Jennifer and Costa, Marta and Begum, Sharmin and Phillimore, Ben and Chambers, Tim and Nye, Emma and Graca, Sofia and Al Bakir, Maise and Hartley, John A and Lowe, Helen L and Herrero, Javier and Lawrence, David and Hayward, Martin and Panagiotopoulos, Nikolaos and Kolvekar, Shyam and Falzon, Mary and Borg, Elaine and Simeon, Celia and Hector, Gemma and Aranda, Marie and Novelli, Marco and Oukrif, Dahmane and Janes, Sam M and Thakrar, Ricky and Forster, Martin and Ahmad, Tanya and Lee, Siow Ming and ... and Melanoma TRACERx Consortium and Renal TRACERx Consortium and Lung TRACERx Consortium
Immunity, ISSN 1074-7613, 04/2017, Volume 46, Issue 4, pp. 577 - 586
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies... 
regulatory T cells | tumor immunotherapy | anti-CD25 | Treg depletion | inhibitory Fc receptor | CD25 | tumor microenvironment | Fc gamma receptors | anti-PD-1 | EFFECTOR | RESPONSES | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | CANCER-PATIENTS | MELANOMA | MONOCLONAL-ANTIBODY | ANTI-CTLA-4 ANTIBODIES | IMMUNOLOGY | ANTITUMOR-ACTIVITY | COMBINATION | GAMMA-RS | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocyte Depletion | Receptors, IgG - metabolism | T-Lymphocytes, Regulatory - immunology | Neoplasms - therapy | Flow Cytometry | Immunoglobulin Fc Fragments - immunology | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - immunology | Kaplan-Meier Estimate | Programmed Cell Death 1 Receptor - metabolism | Receptors, IgG - immunology | Protein Binding - immunology | Animals | Neoplasms - immunology | K562 Cells | Cell Line, Tumor | Mice | Antibodies, Monoclonal - metabolism | Programmed Cell Death 1 Receptor - immunology | Neoplasms - pathology | Viral antibodies | Cell death | Analysis | Immunotherapy | Antibodies | T cells | Cancer | Fc receptors | Beer | Immunoglobulins | Lymphatic system | Immune response | Cytokines | Melanoma | Light emitting diodes | Lymphocytes T | Anticancer properties | Depletion | Lymphocytes | Tumors | Immune system | Report
Journal Article